Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimens

Acalabrutinib plus venetoclax and rituximab in MCL & the importance of chemotherapy-free regimensПодробнее

Venetoclax, lenalidomide + rituximab: a chemotherapy-free regimen for previously untreated MCLПодробнее

Standard of care treatment approaches in MCL and the role of chemotherapy-free regimensПодробнее

Acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or R/R MCLПодробнее

Rationale for Combining Acalabrutinib With Bendamustine and Rituximab in MCLПодробнее

Safety and Efficacy Findings for Acalabrutinib Plus Bendamustine and Rituximab in MCLПодробнее

Advancements in MCL treatmentПодробнее

Ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed MCLПодробнее

Acalabrutinib plus venetoclax and rituximab in the treatment of MCLПодробнее

Acalabrutinib and rituximab as first-line therapy for older patients with MCLПодробнее

Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCLПодробнее

Chemotherapy-free treatment for MCL: success from the WINDOW-2 trialПодробнее

Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCLПодробнее

Dr. Wang on Addition of Acalabrutinib to Bendamustine/Rituximab in MCLПодробнее

TrAVeRse: acalabrutinib + venetoclax and rituximab for treatment-naïve MCLПодробнее

The RELEVANCE study: lenalidomide plus rituximab vs. rituximab-chemotherapy in the treatment of FLПодробнее

NHL33 ‘WAMM’ study: sandwich approach of acalabrutinib plus rituximab and chemotherapy & ASCT in MCLПодробнее

Treatment approaches for older patients with MCLПодробнее

The latest CLL treatments and therapies with Dr Jan BurgerПодробнее

Dr. Phillips on the Safety of Acalabrutinib Plus Bendamustine/Rituximab in MCLПодробнее